Clinical Trial Update: Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LC [Phase 2]

View source ↗

Summary

Phase II study of recMAGE-A3+AS15 ASCI with or without Poly IC:LC in melanoma was terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• recMAGE-A3+AS15 ASCI (recMAGE-A3+AS15 ASCI)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Melanoma | Phase 2 | Status: TERMINATED | Results posted: 2019-12-20